These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27342144)

  • 1. Role of protein S in castration-resistant prostate cancer-like cells.
    Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
    Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
    Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
    Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
    Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
    Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
    Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
    Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
    Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
    Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
    Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
    Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylselenocysteine preventing castration-resistant progression of prostate cancer.
    Liu Y; Liu X; Guo Y; Liang Z; Tian Y; Lu L; Zhao X; Sun Y; Zhao X; Zhang H; Dong Y
    Prostate; 2015 Jun; 75(9):1001-8. PubMed ID: 25754033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
    Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
    Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression.
    Huang SY; Huang GJ; Hsieh PF; Wu HC; Huang WC
    Prostate; 2019 Sep; 79(13):1543-1552. PubMed ID: 31299104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.